Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report

Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report

Non‐small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancer cases. Stage III NSCLC represents a highly heterogenous stage characterized by different disease presentations and a wide range of treatment options. For patients with good performance status and unresectable-stage III NSCLC...

Full description

Bibliographic Details
Main Authors: Paola Maria Medusa, Marina Gilli, Luca Notizia, Raffaella Pagliaro, Nicola Carro, Alessandro Moriello, Vito D'Agnano, Andrea Bianco, Fabio Perrotta, Fabiana Vitiello
Format: Article
Language:English
Published: PAGEPress Publications 2022-11-01
Series:Monaldi Archives for Chest Disease
Subjects:
Stage III NSCLC
elderly patient
immunotherapy
pembrolizumab
PD-L1
Online Access:https://www.monaldi-archives.org/index.php/macd/article/view/2440

Internet

https://www.monaldi-archives.org/index.php/macd/article/view/2440

Similar Items